Company news
Prescient Therapeutics Limited news in 2016
Prescient Therapeutics Limited's news releases, calls and decks from 2016, newest first.
PTX-200 Breast Cancer Trial Progresses
February 16, 2016
Steven Yatomi-Clarke Appointed CEO
February 15, 2016
December 2015 Appendix 4C - Quarterly
February 11, 2016
Virax secures $3 million placement
February 10, 2016
Virax close out of VIR201 HIV Vaccine Phase IIa Trial
February 10, 2016
VIR201 HIV Vaccine Phase IIa Trial Results - 16 August 2010
February 10, 2016
Vhl to acquire deep AKT inhibitor portfolio
February 10, 2016
Update on VIR201 HIV Vaccine Clinical Trial - 9 August 2010
February 10, 2016
Transgene TG4010 Exclusive Option
February 10, 2016
Transgene Announces Topline Preliminary Results
February 10, 2016
SPP Fully Underwritten up to target amount of $1.03 million
February 10, 2016
September 2015 Appendix 4C - Quarterly
February 10, 2016
Prescient completes acquisition of AKTivate Therapeutics
February 10, 2016
Half Yearly Report and Accounts
February 10, 2016
FDA IND Re-Activation Request for Phase Ib/II Trial
February 10, 2016
FDA Allows PTX IND for Leukemia Phase Ib & II Trials
February 10, 2016
Eligible Shareholder Offer Document Mailing - 6 June 2011
February 10, 2016
Co-X-Gene Sub Licence and TG4001 - 24 February 2011
February 10, 2016
Convertible Notes - Quarterly Report - 29 January 2010
February 10, 2016
Capital Raising Update
February 10, 2016
Appendix 4E 30 June 2011
February 10, 2016
Appendix 4D - Half Year 31 December 2009
February 10, 2016
Additional Placement Raises $1.0 million
February 10, 2016
1 for 2 Rights Offer - 25 May 2011
February 10, 2016
Decks in 2016
- Rodman & Renshaw 18th Annual Global Investment Conference (September 2016)
Conference · 33 slides · Sep 13, 2016
- Investor Presentation (April 2016)
Investor deck · 28 slides · Apr 13, 2016
- Biotech Showcase 2016
Conference · 27 slides · Jan 11, 2016